The journal of clinical outcome assessment operations
Regulatory Evidence
How trial teams file endpoint decisions, SAP revisions, eCOA validation, and committee outputs across TMF Reference Model zones for inspection readiness under ICH E6(R3) and EU CTR.
· · 25 min read
Latest
Evidence before assertionHow clinical trial teams derive site feasibility questions from protocol endpoints to verify assessment capabilities, score red flags, and inform risk-based monitoring.
How clinical trial teams bind a newly approved eConsent version to already-enrolled participants without treating an upload as reconsent or overwriting original records.
How clinical trial teams bind the current IRB-approved version, an attributable signature, and the participant copy in REDCap before opening enrollment.
How clinical trial teams write executable endpoint definitions in ICH M11 Section 3, integrating SPIRIT-Outcomes elements and aligning Sections 1.3, 7, 8, and 10.
Operationalize COA translation and cultural adaptation in multinational trials, from respondent debriefing to the statistical evidence required to pool endpoint data.
After a named COA is chosen, which reliability, construct-validity, and ability-to-detect-change results still support using that score as a trial endpoint.
How clinical trial teams construct endpoints from fit-for-purpose COAs and prespecify meaningful-change interpretation plans under draft PFDD Guidance 4.
How clinical development teams can evaluate FDA's surrogate endpoint table across indication, mechanism, and approval pathway without conflating listing with formal qualification.
A methodological guide for clinical development and biostatistics teams on FDA, EMRN V02, and ICH E6(R3) Annex 2 rules for collecting trial endpoints away from traditional sites.
A methodological guide to identifying critical-to-quality endpoint factors under ICH E8(R1) and locking definitions, estimands, and feasibility before protocol freeze.
